Ignite Creation Date:
2025-12-25 @ 4:59 AM
Ignite Modification Date:
2025-12-26 @ 3:59 AM
Study NCT ID:
NCT01739218
Status:
COMPLETED
Last Update Posted:
2019-08-13
First Post:
2012-11-28
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-02-01
Start Date Type:
ACTUAL
Primary Completion Date:
2016-08-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-08-17
Completion Date Type:
ACTUAL
First Submit Date:
2012-11-28
First Submit QC Date:
None
Study First Post Date:
2012-12-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-08-09
Last Update Post Date:
2019-08-13
Last Update Post Date Type:
ACTUAL